Molecular imaging and therapeutic efficacy of 188Re-(DXR)-liposome-BBN in AR42J pancreatic tumor-bearing mice.

Liposomes are good candidates as drug carriers and have been widely investigated in drug delivery systems. In this study, a new combination of bimodal 188Re-(DXR)-liposome-BBN radiochemotherapeutics was designed and studied for treating solid pancreatic tumor by intravenous administration. The in vivo nuclear microSPECT/CT imaging of tumor targeting, prolonged survival time and therapeutic efficacy were evaluated in AR42J malignant pancreatic solid tumor-bearing nude mice. MicroSPECT/CT imaging of 188Re-liposome-BBN pointed to significant targeting in tumors at 24 h after intravenous injection (SUV=2.13 ± 0.98). Co-injection of a blocking dose of cold BBN (4 mg/kg) inhibited the accumulation of 188Re-liposome-BBN in tumors (SUV=1.82 ± 0.31). For therapeutic efficacy, inhibition of tumor growth in mice treated with 188Re-DXR-liposome-BBN was precisely controlled [mean growth inhibition rate (MGI) = 0.092] and had longer survival time [life-span (LS) = 86.96%] than those treated with anticancer drug 188Re-liposome-BBN (MGI = 0.130; LS = 75%), Lipo-Dox-BBN (MGI = 0.666; LS = 3.61%) and untreated control mice. An additive tumor regression effect was observed (CI 0.946) for co-delivery of 188Re-DXR-liposome-BBN radiochemotherapeutics. These results point to the potential benefit of the 188Re-(DXR)-liposome-BBN radiochemotherapeutics for adjuvant cancer treatment with applications in oncology.
AuthorsYa-Jen Chang, Chia-Yu Yu, Chin-Wei Hsu, Wan-Chi Lee, Su-Jung Chen, Chih-Hsien Chang, Te-Wei Lee
JournalOncology reports (Oncol Rep) Vol. 28 Issue 5 Pg. 1736-42 (Nov 2012) ISSN: 1791-2431 [Electronic] Greece
PMID22922965 (Publication Type: Journal Article)
Chemical References
  • Organometallic Compounds
  • Radiopharmaceuticals
  • Rhenium
  • Doxorubicin
  • Bombesin
  • Administration, Intravenous
  • Animals
  • Bombesin (pharmacology, therapeutic use)
  • Cell Line, Tumor
  • Chemoradiotherapy
  • Doxorubicin (pharmacology, therapeutic use)
  • Humans
  • Mice
  • Multimodal Imaging
  • Organometallic Compounds (pharmacology, therapeutic use)
  • Pancreatic Neoplasms (mortality, therapy)
  • Positron-Emission Tomography
  • Radiopharmaceuticals (pharmacology, therapeutic use)
  • Rhenium (chemistry, pharmacology, therapeutic use)
  • Tissue Distribution
  • Tomography, X-Ray Computed
  • Xenograft Model Antitumor Assays

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: